Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | TK2 | O00142 | 1/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22560281 | 1.00 | TK1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL21071421 | 1.00 | TK1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL5982324 | 1.00 | TK1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL21115874 | 1.00 | TK1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL5982320 | 1.00 | TK1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL5983081 | 0.90 | TK1 (0.57) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL5982403 | 0.89 | TK1 (0.64) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL5983317 | 0.89 | TK1 (0.64) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL9780661 | 0.87 | TK1 (0.69) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL5983020 | 0.87 | TK1 (0.69) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10866219-B2 | Method for detecting trifluridine- and/or tipiracil-related substance | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-15 | — | — | US | disclosed |
| EP-3736568-A1 | DETECTION METHOD FOR ANALOG DERIVED FROM TRIFLURIDINE | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-11-11 | — | — | EP | disclosed |
| EP-3730935-A1 | METHOD FOR DETECTING TRIFLURIDINE- AND/OR TIPIRACIL-DERIVED ANALOGS | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-28 | — | — | EP | disclosed |
| US-10816517-B2 | Method for detecting trifluridine-related substance by high-performance liquid chromatography | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-27 | — | — | US | disclosed |
| US-20190212309-A1 | METHOD FOR DETECTING TRIFLURIDINE-RELATED SUBSTANCE BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-07-11 | — | — | US | disclosed |
| US-20190195840-A1 | METHOD FOR DETECTING TRIFLURIDINE- AND/OR TIPIRACIL-RELATED SUBSTANCE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190195840-A1 | METHOD FOR DETECTING TRIFLURIDINE- AND/OR TIPIRACIL-RELATED SUBSTANCE | SLC6A5, TPMT, SLC1A5 | TK1 592/4885LMNA 4664/4885SMN1; SMN2 3186/4885 |
| US-10866219-B2 | Method for detecting trifluridine- and/or tipiracil-related substance | SLC6A5, TPMT, SLC1A5 | TK1 592/4885LMNA 4664/4885SMN1; SMN2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.